Juno Looks To Move CAR-T To Solid Tumors Via Editas Deal
This article was originally published in The Pink Sheet Daily
Deal brings Juno access to CRIPSR genomic-editing technology, one of four deals in the past five weeks aimed at keeping the immuno-oncology biotech on the cutting edge.
You may also be interested in...
CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.
Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.